PROVENGE Resources

Find PROVENGE resources for you, your office, and your patients

Below is a list of of useful resources. For more information about the PROVENGE Support Services—including enrolling patients for PROVENGE therapy, patient assistance, reimbursement support, or facilitating the treatment process—please talk to your Dendreon Sales Representative or call Dendreon ON Call at 1-877-336-3736.

PROVENGE Forms: Find forms to help facilitate treatment of your PROVENGE patients.
- Get started with the Patient Enrollment Form. Download Now.
Product Information: Find clinical resources about PROVENGE.
- Phase 3 IMPACT Trial Results Published in the New England Journal of Medicine. Review Results.
Reimbursement Resources: Find useful tools and information to simplify the reimbursement process.
- Read about important NCD and Q-code information. Learn more.
Treatment Support Resources (for Infusion Sites): Find clinical resources designed to support the treatment process.
- Access the PROVENGE Full Prescribing Information now. Learn more.
Resources for Patients: Find patient education materials to help patients learn about PROVENGE.
- View the patient education brochure. Learn more.
Media Resources for Practices: Find resources to support your efforts in increasing awareness regarding the availability of PROVENGE.
- View the Press Release template. Login to learn more.

Next: PROVENGE Forms

INDICATION

PROVENGE^® (sipuleucel-T) is approved by the FDA as an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥ 15%) reported in the PROVENGE group were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

Dendreon supports all prostate cancer advocates in their efforts to help raise awareness of prostate cancer and improve the lives of those living with prostate cancer. Please click on the organizations displayed to find out what they are doing in support of Prostate Cancer Awareness, including possible events in your community. And, you can show your support for Prostate Cancer Awareness by clicking on the badges to the right to post to your personal site, Twitter page (use 112px x 112px), or Facebook page (use 230px x 65px).